Omer Faruk Karataş - Genetic Mutations

Author Information

Omer Faruk Karatas is a prominent researcher affiliated with the Molecular Biology and Genetics Department at Erzurum Technical University in Erzurum, Turkey. His work is primarily focused on the field of genetics, with significant contributions in cancer research, particularly prostate cancer. He is noted for his expertise and innovative approaches in understanding oncogenic drivers and the molecular mechanisms underlying various cancers.

Research Contributions

Omer Faruk Karatas has made substantial contributions to the field of cancer genetics, as evidenced by his numerous publications in 2021. His research spans a diverse array of topics, including the role of MEX3D as an oncogenic driver in prostate cancer, the potential use of microRNA-4484 as a biomarker for peri-implantitis, and the mechanisms of drug resistance in cancer therapy. He has also explored the effects of natural compounds like Daucus carota extract on prostate cancer cells and investigated the synthesis of novel chemical derivatives as potential cancer therapeutics. His work extends to understanding the molecular pathways involved in cancer, such as the FGFR/Akt/SOX2 axis in overcoming drug resistance and the transcriptional regulation by microRNA-145.

Aliases

Omer Faruk Karatas is known by several aliases in academic publications, including Omer Faruk Karataş, Omer Karataş, Omer F. Karatas, and O. Faruk Karataş. These variations in name spellings are common in scientific literature and reflect transliterations and abbreviations of his full name.

Publication and Citation Metrics

Metric Value
Citation Count 1891
H-index 25
Paper Count 140

Publications:

DOI: 10.1002/pros.24216

Year: 2021

DOI: 10.1111/jfbc.13975

Year: 2021

DOI: 10.11607/jomi.8470

Year: 2021

DOI: 10.1002/cbin.11554

Year: 2021

DOI: 10.1038/s41391-021-00353-0

Year: 2021

DOI: 10.1007/s13402-021-00645-6

Year: 2021

DOI: 10.1007/s11033-021-06167-6

Year: 2021

DOI: 10.1002/ardp.202100225

Year: 2021

DOI: 10.1080/19396368.2021.2003481

Year: 2021

DOI: 10.1111/odi.14117

Year: 2021

Frequently asked queries:
How do Chemical Mutagens Cause Induced Mutations?
What are the Implications for Carriers?
How Do These Tools Improve Diagnosis?
What is Immunotherapy?
What Causes Cellular Heterogeneity?
Why is Karyotyping Important in the Context of Genetic Mutations?
What is the Future of CFTR Gene Research?
How Does the Body Repair UV-Induced DNA Damage?
Are Synonymous Mutations Considered in Genetic Research?
Who Should Consider PARP Inhibitors?
Follow Us
Top Searches
Autism Spectrum Disorder Congenital Heart Disease Cystic Fibrosis DNA Cloning Fragile X Syndrome Huntington’s Disease Livestock Lynch Syndrome Neurodegenerative Diseases Sickle Cell Disease Thalassemia Patients

Partnered Content Networks

Relevant Topics